Daiichi Sankyo received FDA approval of Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination drug taken once-daily for the treatment of hypertension in patients who are not adequately controlled with other antihypertensive drug classes including: angiotensin receptor blockers, calcium channel blockers and diuretics. Tribenzor combines three widely prescribed antihypertensive medications, each working in a different way, to lower blood pressure. It...